Tirzepatide Matches Competitor's Cardioprotective Benefits for Diabetics
(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide…
(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide…
(MedPage Today) — In one of the shortest speeches of his presidency so far, President Trump on Wednesday evening suggested…
(MedPage Today) — Multiple studies have linked alcohol consumption to an increased risk of breast cancer, and binge drinking may…
(MedPage Today) — Note that some links may require registration or subscription. UnitedHealth is facing wrongful death lawsuits related to…
(MedPage Today) — Teen use of alcohol, nicotine, and marijuana remains at record lows, according to national survey results released…
(MedPage Today) — An MIT Media Lab study published this past summer has ignited an unusually intense debate about what…